Olaparib after Initial Treatment Delays Ovarian Cancer Progression


In a recent trial, the PARP inhibitor olaparib substantially delayed ovarian cancer from coming back after the first line of chemotherapy. Could the findings change the standard of care for newly diagnosed ovarian cancer with a BRCA mutation?

Powered by WPeMatico